Jan Terje Andersen receives a grant of 8.5 million NOK from NANO2021

Jan Terje Andersen
Jan Terje Andersen

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, is studying the cellular processes and molecular interplay underlying the functions of the two most abundant proteins in blood, albumin and IgG. By combining structural and biophysical approaches with cellular and in vivo studies, they use the insights to design novel albumin and antibody molecules with improved functions. The research group has now received a grant of 8.5 million NOK from The research Council of Norway (NANO2021 program) to expand their work on how such engineered ligands can be explored in combination with nanoparticles for tailored mucosal delivery. The project is entitled “A novel nanoparticle-based approach for mucosal delivery of therapeutics".
There were 61 applicants, of which two (including this application) obtained the highest possible rate. 

The other receiving top rating was Maria Torgersen, also from Oslo University Hospital, a member of Kirsten Sandvig's "Intracellular Transport Group" at the Department of Molecular Cell Biology at the Institute for Cancer Research.

Nanotechnology and Advanced Materials (NANO2021) is the Research Council of Norway’s large-scale programme for research on nanotechnology, microtechnology and advanced materials, and will run from 2012 to 2021.

From the home page of the Research Council of Norway:
Home page - Nanotechnology and Advanced Materials (NANO2021)

Programme description - NANO2021

Home page of Jan Terje Andersen's group - The Laboratory of Adaptive Immunity and Homeostasis

Institute of Immunology

Division of Laboratory Medicine 

Previous news involving Jan Terje Andersen:

Fridtjof Nansen Award 2015:
Fridtjof Nansen awards for excellent research to Anne-Lise Børresen-Dale and Jan Terje Andersen

Excellent Researcher Award 2015:
Oslo University Hospital honouring excellent research


Page visits: 4768